Flagship Biosciences finds Arizona a great home for serving pathology digitally

June 5, 2012

While most of Flagship’s customers are at biotech and pharma locations around the world, there has been some strong collaborations formed with Arizona biotech firms. “The collaboration spirit in Arizonais remarkable” said Steve Potts. “the amount of additional business that Arizona groups like TGEN generate for other local biotech providers is astonishing. It has been an honor to work with Steve Gately’s TGEN Drug Development group (TD2), with a number of completed projects where TD2 applies their unique oncology expertise and Flagship adds our quantitative pathology.”

Arizona has a number of worldclass specialty contract research organizations, including TD2 in Oncology, Flagship Biosciences in pathology, Imaging Endpoints in radiology, Medelis in oncology and dermatology clinical trials, and SDC in statistics. The need for best-in-class specialty service is growing in the pharmaceutical industry, and Arizona with a skilled workforce, strong collaborative spirit, and industry friendly environment is positioned to lead in this area.

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.